dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Grau Vorster, Marta |
dc.contributor.author | Lopez Montañes, Maria |
dc.contributor.author | Canto Puig, Ester |
dc.contributor.author | Vives Armengol, Joaquim |
dc.contributor.author | Oliver-Vila, Irene |
dc.contributor.author | Barba Suñol, Pere |
dc.contributor.author | Rudilla Salvador, Francesc |
dc.date.accessioned | 2021-09-08T07:38:53Z |
dc.date.available | 2021-09-08T07:38:53Z |
dc.date.issued | 2020-02-25 |
dc.identifier.citation | Grau-Vorster M, López-Montañés M, Cantó E, Vives J, Oliver-Vila I, Barba P, et al. Characterization of a Cytomegalovirus-Specific T Lymphocyte Product Obtained Through a Rapid and Scalable Production Process for Use in Adoptive Immunotherapy. Front Immunol. 2020 Feb 25;11:271. |
dc.identifier.issn | 1664-3224 |
dc.identifier.uri | https://hdl.handle.net/11351/6278 |
dc.description | Adoptive immunotherapy; Cytotoxicity; Virus specific T lymphocytes (VST) |
dc.description.abstract | Immunosuppressed patients are susceptible to virus reactivation or de novo infection. Adoptive immunotherapy, based on virus-specific T lymphocytes (VST), can prevent or treat viral diseases. However, donor availability, HLA-compatibility restrictions, high costs, and time required for the production of personalized medicines constitute considerable limitations to this treatment. Ex vivo rapid and large-scale expansion of VST, compliant with current good manufacturing practice (cGMP) standards, with an associated cell donor registry would overcome these limitations. This study aimed to characterize a VST product obtained through an expansion protocol transferable to cGMP standards. Antigenic stimulus consisted of cytomegalovirus (CMV) pp65 peptide pool-pulsed autologous dendritic cells (DCs) derived from monocytes. G-Rex technology, cytokines IL-2, IL-7, and IL-15, and anti-CD3 and anti-CD28 antibodies were used for culture. At day 14 of cell culture, the final product was characterized regarding T cell subsets, specificity, and functionality. The final product, comprised mainly CD4+ and CD8+ T lymphocytes (49.2 ± 24.7 and 42.3 ± 25.2, respectively). The culture conditions made it possible to achieve at least a 98.89-fold increase in pp65-specific CD3+ IFN-γ+ cells. These cells were specific, as pp65-specific cytotoxicity was demonstrated. Additionally, in complete HLA mismatch and without the presence of pp65, alloreactivity resulted in <5% cell lysis. In conclusion, a cGMP scalable process for the generation of a large number of doses of CMV-specific cytotoxic T cells was successfully performed. |
dc.language.iso | eng |
dc.publisher | Frontiers Media |
dc.relation.ispartofseries | Frontiers in Immunology;11 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Infeccions per citomegalovirus |
dc.subject | Cèl·lules T |
dc.subject | Immunoteràpia |
dc.subject.mesh | Immunotherapy, Adoptive |
dc.subject.mesh | T-Lymphocytes, Cytotoxic |
dc.subject.mesh | Cytomegalovirus Infections |
dc.title | Characterization of a Cytomegalovirus-Specific T Lymphocyte Product Obtained Through a Rapid and Scalable Production Process for Use in Adoptive Immunotherapy |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3389/fimmu.2020.00271 |
dc.subject.decs | infecciones por Citomegalovirus |
dc.subject.decs | inmunoterapia adoptiva |
dc.subject.decs | linfocitos T citotóxicos |
dc.relation.publishversion | https://doi.org/10.3389/fimmu.2020.00271 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Grau-Vorster M, López-Montañés M, Cantó E, Rudilla F] Cell Therapy Service, Banc de Sang i Teixits, Barcelona, Spain. Grup de Medicina Transfusional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Vives J] Cell Therapy Service, Banc de Sang i Teixits, Barcelona, Spain. Grup de Medicina Transfusional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Grup d’Enginyeria tissular musculoesquelètica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Oliver-Vila I] Cell Therapy Service, Banc de Sang i Teixits, Barcelona, Spain. [Barba P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain |
dc.identifier.pmid | 32161589 |
dc.identifier.wos | 000524779300001 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/RD16%2F0011%2F0028 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PERIS2016-2020/2017SGR719 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |